Yousef Almahanna

Yousef Almahanna

Auto-generated profile, based on publicly available information

Yousef Almahanna

Division of Gastroenterology and Hepatology, Western University & London Health Sciences Centre, London, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in American Journal of Gastroenterology
Verified
Journal Article
Open access
NANaim Alkhouri
Naim Alkhouri
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
LCLaurent Castera
Laurent Castera
MTMarina Takawy
Marina Takawy
LALeon A. Adams
Leon A. Adams
WDWinston Dunn
Winston Dunn
INTRODUCTION: The recent US Food and Drug Administration approval of resmetirom for treating metabolic dysfunction-associated steatohepatitis in patients necessitates patient selection for significant fibrosis or higher (≥F2). No existing vibration-controlled transient elastography (VCTE) algorithm targets ≥F2. METHODS: The mAchine Learning ADvanceD fibrosis and rIsk metabolic dysfunction-associated steatohepatitis Novel predictor (ALADDIN) study addressed this gap by introducing a machine-learning-based web calculator that estimates the likelihood of significant fibrosis using routine laboratory parameters with and without VCTE. Our study included a training set of 827 patients, a testing set of 504 patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease from 6 centers, and an external validation set of 1,299 patients from 9 centers. Five algorithms were compared using area under the curve (AUC) in the test set: ElasticNet, random forest, gradient boosting machines, XGBoost, and neural networks. The top 3 (random forest, gradient boosting machines, and XGBoost) formed an ensemble model. RESULTS: In the external validation set, the ALADDIN-F2-VCTE model, using routine laboratory parameters with VCTE (AUC 0.791, 95% confidence interval [CI]: 0.764–0.819), outperformed VCTE alone (0.745, 95% CI 0.717–0.772, P < 0.0001), FibroScan-aspartate aminotransferase (0.710, 0.679–0.748, P < 0.0001), and Agile-3 model (0.740, 0.710–0.770, P < 0.0001) regarding the AUC, decision curve analysis, and calibration. The ALADDIN-F2-Lab model, using routine laboratory parameters without VCTE, achieved an AUC of 0.706 (95% CI: 0.668–0.749) and outperformed Fibrosis-4, steatosis-associated fibrosis estimator, and LiverRisk scores. DISCUSSION: Along with the steatosis-associated fibrosis estimator model developed to target significant fibrosis or higher, ALADDIN-F2-VCTE (https://aihepatology.shinyapps.io/ALADDIN1) uniquely supports a refined noninvasive approach to patient selection for resmetirom without the need for liver biopsy. In addition, ALADDIN-F2-Lab (https://aihepatology.shinyapps.io/ALADDIN2) offers an effective alternative when VCTE is unavailable.

27 November 2025 in Annals of Hepatology
Verified
Journal Article
Open access
YAYousef Almahanna
Yousef Almahanna
FIFrancisco Idalsoaga
Francisco Idalsoaga
LDLuis Antonio Díaz
Luis Antonio Díaz
AAAhmed Almohsen
Ahmed Almohsen
YSYi Nong Song
Yi Nong Song
JAJuan Pablo Arab
Juan Pablo Arab
Steatotic liver disease (SLD) affects 40 % of North Americans, with some progressing to advanced fibrosis. A recent nomenclature update redefined subtypes, distinguishing Metabolic dysfunction-associated steatotic liver disease (MASLD), Metabolic and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD). This study aimed to assess the prevalence of MetALD and ALD in a previously Non-alcoholic fatty liver disease (NAFLD) -labeled cohort, evaluate cardiometabolic risk factors, and analyze short-term outcomes. This retrospective observational cohort study included patients referred to a specialized NAFLD clinic in Ontario, Canada (October 2021-September 2023). Adults (age ≥18 years) with radiographic hepatic steatosis were categorized into MASLD, MetALD, or ALD based on gender-specific alcohol consumption thresholds documented in electronic medical records. Baseline characteristics and short-term outcomes were compared across groups. Among 445 patients, MASLD was most prevalent (88.3 %), followed by MetALD (8.9 %) and ALD (2.7 %). Males predominated in MetALD (67.5 %) and ALD (83.4 %) (p = 0.002). Smoking was strongly linked to ALD (p = 0.001). Diabetes was more common in MASLD (32.5 %, p = 0.012), while hypertension and dyslipidemia showed no significant differences across SLD subtypes. Advanced fibrosis (F3-F4) was present in 16.1 %. In a two-year follow-up, higher mortality incidences were observed in ALD (16.6 %). Additionally, regression of fibrosis was observed across all groups. 11.7 % of patients historically labeled as NAFLD met criteria for MetALD or ALD, underscoring the importance of updated nomenclature. High fibrosis prevalence and ALD-related mortality highlight the need for early screening, precise alcohol assessment, and multidisciplinary care to improve outcomes.